Management attributes the 22% revenue growth to a global shift toward decentralized testing, particularly in the U.S. where established reimbursement rates and improved denial rates are incentivizing hospitals to scale in-house genomics. The record 108,000 genomic analyses performed in Q1 reflects an accelerating 'adoption loop' where increased data volume improves AI algorithm accuracy, fostering deeper institutional trust and further platform expansion. Operational efficiency gains were driven by th ...